interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Lanthanum Carbonate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Lanthanum Carbonate, and who makes it?

Lanthanum Carbonate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 4 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 12.8 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Lanthanum Carbonate2 dosage-form groups in the Orange Book
4generic makers listed
  1. Lanthanum Carbonate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 4 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 12.8 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Chewable, Oral

Four or more generic makers listed

Brand listed as marketed: Fosrenol. 4 generic makers with 12 generic products listed as marketed; the first generic approval is dated 11 August 2017.

200020052010201520202025203004brand 2004Natco Pharma Ltd, first approval 11 August 2017Invagen Pharmaceuticals Inc, first approval 24 January 2022Barr Laboratories Inc A Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc, first approval 27 January 2022Alkem Laboratories Ltd, first approval 13 March 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Natco Pharma Ltd11 August 20173
Invagen Pharmaceuticals Inc24 January 20223
Barr Laboratories Inc A Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc27 January 20223
Alkem Laboratories Ltd13 March 20253

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Powder, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Fosrenol. No generic is listed as marketed.

2010201520202025203001brand 2014data datePatent 8980327 listed to expire 1 December 2030Patent 9023397 listed to expire 1 December 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 1 December 2030Patent 8980327 drug product
  • 1 December 2030Patent 9023397 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.